Article
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2024
Passaro A, Wang J, Wang Y, Lee S-H, Melosky B, Shih J-Y, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot A B, Califano R, Cappuzzo F, Owen S, Popat S, Tan J-L, Salinas J, Tomasini P, Gentzler R D, William W N, Reckamp K L, Takahashi T, Ganguly S, Kowalski D M, Bearz A, MacKean M, Barala P, Bourla A B, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch R E, Bauml J M, Campelo R G, Cho B C
Abstract excerpt
BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. PATIENTS AND METHODS: A total of 657 patients with EGFR-mutated (exon 19 deletions or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.